Sprint Bioscience Management

Management criteria checks 2/4

Sprint Bioscience’s CEO is Mathias Skalmstad, appointed in Aug 2021, he has a tenure of 1.8yrs. he directly owns 0.027% of the company’s shares, worth kr13.1k. The average tenure of the management team and the board of directors is 14.3yrs and 3.7yrs respectively.

Key information

Mathias Skalmstad

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.8yrs
CEO ownership	0.03%
Management average tenure	14.3yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Feb 19

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Nov 19

CEO

Mathias Skalmstad (49 yo)

1.8yrs

Tenure

Mr. Mathias Skalmstad is Chief Financial Officer of Sprint Bioscience AB (publ) from August 16, 2021 and is its Acting Chief Executive Officer since January 23, 2023. He has a number of different experienc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mathias Skalmstad	Acting CEO and CFO	1.8yrs	no data	0.027% SEK 13.1k
Pär Nordlund	Founder	no data	kr25.00k	0.91% SEK 440.3k
Martin Andersson	Co-Founder & Chief Scientific Officer	14.3yrs	no data	0.38% SEK 184.3k
Jessica Martinsson	Founder	14.3yrs	kr2.00m	0.38% SEK 184.7k
Kenth Hallberg	Founder & Director of Structural Chemistry	no data	no data	no data
Anne-Marie Wenthzel	Chief Business Officer	no data	no data	0.25% SEK 120.3k

14.3yrs

Average Tenure

51yo

Average Age

Experienced Management: SPRINT's management team is seasoned and experienced (14.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Svein Mathisen	Independent Director	3.3yrs	kr171.00k	0.032% SEK 15.5k
Lewis Cantley	Member of Scientific Advisory Board	no data	no data	no data
Rune Nordlander	Director	13.3yrs	kr171.00k	7.48% SEK 3.6m
Robert Devita	Member of Scientific Advisory Board	no data	no data	no data
Fredrik Lehmann	Independent Director	4yrs	kr125.00k	0.021% SEK 10.3k
Bjorn Sjostrand	Independent Chairman of the Board	2.3yrs	kr159.00k	0.63% SEK 304.4k
Gunilla Enblad	Member of Scientific Advisory Board	no data	no data	no data

3.7yrs

Average Tenure

66yo

Average Age

Experienced Board: SPRINT's board of directors are considered experienced (3.7 years average tenure).

Sprint Bioscience Management

Management criteria checks 2/4

Key information

Recent management updates

High number of new and inexperienced directors

Interim Chief Executive Officer Charlotte Leife has left the company

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

Recent updates

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)

Price target decreased to kr3.30

Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)

Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)

First quarter 2022 earnings: EPS misses analyst expectations

Sprint Bioscience Launches NIMA at BIO International

Forecast to breakeven in 2023

High number of new and inexperienced directors

Full year 2021 earnings: EPS misses analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations

Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)

Director recently bought kr336k worth of stock

Sprint Bioscience AB (publ) Adds New Cancer Drug Program to its Project Portfolio

Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)

Sprint Bioscience AB (publ) announced that it has received SEK 20.713701 million in funding

Interim Chief Executive Officer Charlotte Leife has left the company

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

Revenue and earnings beat expectations

New 90-day low: kr6.52

Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)

New 90-day low: kr7.10

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Third quarter 2020 earnings released: kr0.36 loss per share

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age